Timothy Stuhlmiller

Timothy Stuhlmiller has an extensive work experience in the scientific and medical field. Timothy currently holds the position of Vice President of Scientific and Medical Affairs at xCures since June 2021. Prior to this role, they served as the Director of Scientific Strategy at xCures from August 2019 to June 2021, and as a Scientific Consultant from March 2019 to August 2019.

Additionally, Timothy is a Co-Founder of Opsepio Therapeutics, Inc, a molecular oncology company that focuses on in-licensing cancer therapeutics. Timothy performed due diligence, bioinformatics, and comparative market analysis, and also developed preclinical research strategies and budgets for the company.

Before their work at xCures and Opsepio Therapeutics, Timothy worked as a Consultant in Scientific Writing at Nuventra Pharma Sciences from March 2019 to August 2019.

Prior to entering the industry, Timothy worked as a Principal Scientist at SPYRYX Biosciences from September 2016 to February 2019. In this role, they performed various research and development tasks, including lead selection of therapeutic peptides, project management, and the development of preclinical research plans and budgets for alternative indications and molecular targets.

Timothy started their career as a Postdoctoral Research Fellow at the University of North Carolina at Chapel Hill from April 2012 to September 2016. During this time, they focused on defining adaptive resistance mechanisms to targeted therapeutics through proteomic analyses and systems-level analysis of molecular responses in various disease models, resulting in high-level publications.

Timothy Stuhlmiller completed their Bachelor of Science degree in Biochemistry and Biology/Biological Sciences from Florida State University between 2002 and 2006. Timothy then pursued a Doctor of Philosophy (PhD) in Molecular, Cellular, and Developmental Biology from Yale University, which they obtained from 2006 to 2011.